{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:28:31Z","timestamp":1790310511980,"version":"4.1.0"},"reference-count":176,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.4103\/sjg.sjg_277_25","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T16:00:28Z","timestamp":1766160028000},"page":"254-297","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Practical guidelines on medical management of adults with moderate-to-severe inflammatory bowel disease"],"prefix":"10.4103","volume":"32","author":[{"given":"Mahmoud H.","family":"Mosli","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, King Abdulaziz University, Inflammatory Bowel Disease Unit, King Abdulaziz University Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badr","family":"Al-Bawardy","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia"},{"name":"Department of Internal Medicine, Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA"},{"name":"College of Medicine, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turki","family":"AlAmeel","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Fahad Specialist Hospital, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla A.","family":"Azzam","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakir A.","family":"Bakkari","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman R.","family":"Alharbi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, College of Medicine, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulelah","family":"Almutairdi","sequence":"additional","affiliation":[{"name":"Department of Medicine, King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser K.","family":"Meeralam","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Digestive and Liver Health and Advanced Endoscopy Center, King Abdullah Medical City, Makkah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar I.","family":"Saadah","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Inflammatory Bowel Disease Unit, King Abdulaziz University Hospital, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid A.","family":"Almadi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, King Khalid University Hospital, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia"},{"name":"Division of Gastroenterology, The McGill University Health Center, Montreal General Hospital, McGill University, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed","family":"Alhazzani","sequence":"additional","affiliation":[{"name":"Health Research Centre, Ministry of Defence Health Services, Riyadh, Saudi Arabia"},{"name":"Department of Critical Care and Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa F.","family":"Alotaibi","sequence":"additional","affiliation":[{"name":"Health Research Centre, Ministry of Defence Health Services, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalidah A.","family":"Alenzi","sequence":"additional","affiliation":[{"name":"Executive Management of Transformation, Planning, and Business Development, Tabuk Health Cluster, Tabuk, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bedor A.","family":"Al-Omari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care Services, Prince Sultan Military Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajer Y.","family":"Almudaiheem","sequence":"additional","affiliation":[{"name":"The Saudi Society of Clinical Pharmacy, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed H.","family":"Al-Jedai","sequence":"additional","affiliation":[{"name":"The Saudi Society of Clinical Pharmacy, Riyadh, Saudi Arabia"},{"name":"Department of Pharmacy Practice, Colleges of Medicine and Pharmacy, Alfaisal University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"R1-20260629","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1201\/9780849381829.ch17","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Hoentjen","year":"2008","journal-title":"Handbook of Prebiotics"},{"key":"R2-20260629","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2468-1253(19)30358-9","article-title":"Global burden of inflammatory bowel disease","volume":"5","author":"Jairath","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R3-20260629","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"R4-20260629","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00535-022-01862-y","article-title":"A review on the current status and definitions of activity indices in inflammatory bowel disease: How to use indices for precise evaluation","volume":"57","author":"Kishi","year":"2022","journal-title":"J Gastroenterol"},{"key":"R5-20260629","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41575-024-01035-7","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R6-20260629","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"R7-20260629","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00535-009-0057-3","article-title":"Prevalence of ulcerative colitis and Crohn's disease in Japan","volume":"44","author":"Asakura","year":"2009","journal-title":"J Gastroenterol"},{"key":"R8-20260629","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-230X-10-32","article-title":"Prevalence of inflammatory bowel disease in two districts of Sri Lanka: A hospital based survey","volume":"10","author":"Niriella","year":"2010","journal-title":"BMC Gastroenterol"},{"key":"R9-20260629","doi-asserted-by":"crossref","first-page":"276","DOI":"10.5144\/0256-4947.2012.276","article-title":"Inflammatory bowel disease in Saudi Arabia: A hospital-based clinical study of 312 patients","volume":"32","author":"Fadda","year":"2012","journal-title":"Ann Saudi Med"},{"key":"R10-20260629","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3748\/wjg.v10.i9.1341","article-title":"Epidemiology and outcome of Crohn's disease in a teaching hospital in Riyadh","volume":"10","author":"Al-Ghamdi","year":"2004","journal-title":"World J Gastroenterol"},{"key":"R11-20260629","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000518003","article-title":"Incidence, prevalence, and clinical epidemiology of inflammatory bowel disease in the Arab world: A systematic review and meta-analysis","volume":"6","author":"Mosli","year":"2021","journal-title":"Inflamm Intest Dis"},{"key":"R12-20260629","first-page":"527","article-title":"Inflammatory bowel disease burden in the Middle East and North Africa Region: A comprehensive analysis of incidence, prevalence, and mortality from 1990-2019","volume":"37","author":"Alsakarneh","year":"2024","journal-title":"Ann Gastroenterol"},{"key":"R13-20260629","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"key":"R14-20260629","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"R15-20260629","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"R16-20260629","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R17-20260629","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: Medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"(Suppl 1)","key":"R18-20260629","first-page":"S1","article-title":"Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease","volume":"29","author":"Mosli","year":"2022","journal-title":"Saudi J Gastroenterol"},{"key":"R19-20260629","article-title":"GRADEpro Guideline Development Tool [software","volume":"435","year":"2015","journal-title":"McMaster Univ"},{"key":"R20-20260629","doi-asserted-by":"crossref","first-page":"101484","DOI":"10.1016\/j.cegh.2023.101484","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin Epidemiol Glob Health"},{"key":"R21-20260629","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R22-20260629","article-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies","year":"2021"},{"key":"R23-20260629","doi-asserted-by":"crossref","first-page":"e8109","DOI":"10.5867\/medwave.2021.02.8109","article-title":"The GRADE approach, Part 1: How to assess the certainty of the evidence","volume":"21","author":"Kirmayr","year":"2021","journal-title":"Medwave"},{"key":"R24-20260629","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"R25-20260629","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2021.10.037","article-title":"Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials","volume":"162","author":"Ben-Horin","year":"2022","journal-title":"Gastroenterology"},{"key":"R26-20260629","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/ibd\/izad149","article-title":"Early biologic treatment decreases risk of surgery in Crohn's disease but not in ulcerative colitis: Systematic review and meta-analysis","volume":"30","author":"Law","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R27-20260629","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): A multicentre, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R28-20260629","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised clinical trial: Deep remission in biologic and immunomodulator na\u00efve patients with Crohn's disease \u2013 A SONIC post hoc analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R29-20260629","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","article-title":"Subgroup analysis of the placebo-controlled charm trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease","volume":"7","author":"Schreiber","year":"2013","journal-title":"J Crohn's Colitis"},{"key":"R30-20260629","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"(Suppl 2)","key":"R31-20260629","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British society of gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"R32-20260629","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"R33-20260629","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"R34-20260629","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"R35-20260629","first-page":"CD012893","article-title":"Certolizumab pegol for induction of remission in Crohn's disease","volume":"8","author":"Yamazaki","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R36-20260629","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1080\/21645515.2019.1591139","article-title":"A product review of vedolizumab in inflammatory bowel disease","volume":"15","author":"Battat","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"R37-20260629","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"R38-20260629","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3892\/etm.2023.11997","article-title":"Efficacy and safety of vedolizumab in the treatment of patients with inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Tang","year":"2023","journal-title":"Exp Ther Med"},{"key":"R39-20260629","first-page":"CD013611","article-title":"Vedolizumab for induction and maintenance of remission in Crohn's disease","volume":"7","author":"Hui","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"R40-20260629","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"R41-20260629","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s10620-021-06932-4","article-title":"Effectiveness and safety of ustekinumab in inflammatory bowel disease: A systematic review and meta-analysis","volume":"67","author":"Honap","year":"2022","journal-title":"Dig Dis Sci"},{"key":"R42-20260629","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn's disease: Results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D'Haens","year":"2022","journal-title":"Lancet"},{"key":"R43-20260629","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jgh.16358","article-title":"Efficacy and safety of risankizumab for Crohn's disease in patients from Asian countries: A post hoc subanalysis of the global phase 3 ADVANCE, MOTIVATE, and FORTIFY studies","volume":"39","author":"Gao","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"R44-20260629","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5114\/ceji.2023.134257","article-title":"Efficacy of IL-23 inhibitors and IL-12\/23 inhibitors in the induction treatment of Crohn's disease: A meta-analysis based on randomized controlled trials","volume":"48","author":"Gao","year":"2023","journal-title":"Cent Eur J Immunol"},{"key":"R45-20260629","first-page":"S","article-title":"Sa1133 efficacy and safety of different doses of risankizumab in Crohn disease: A systematic review and network meta-analysis","volume":"164","author":"Badi","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"R46-20260629","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: Maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R47-20260629","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.gastro.2025.02.033","article-title":"Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study","volume":"169","author":"Hart","year":"2025","journal-title":"Gastroenterology"},{"key":"R48-20260629","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.gastro.2025.02.033","article-title":"Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study","volume":"169","author":"Hart","year":"2025","journal-title":"Gastroenterology"},{"key":"R49-20260629","doi-asserted-by":"crossref","first-page":"i1724","DOI":"10.1093\/ecco-jcc\/jjae190.1091","article-title":"P0917 Corticosteroid sparing effects of treatment with guselkumab in patients with moderate to severely active Crohn's disease: Phase 3 GALAXI 2\/3 results through week 48","volume":"19","author":"Pan\u00e9s","year":"2025","journal-title":"J Crohns Colitis"},{"key":"R50-20260629","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: A phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"R51-20260629","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on therapeutics in Crohn's disease: Medical treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R52-20260629","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.14309\/ajg.0000000000003465","article-title":"ACG clinical guideline: Management of Crohn's disease in adults","volume":"120","author":"Lichtenstein","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"R53-20260629","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"R54-20260629","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"key":"R55-20260629","doi-asserted-by":"crossref","first-page":"e0312603","DOI":"10.1371\/journal.pone.0312603","article-title":"Budget impact analysis of subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in Saudi Arabia: Analysis from payer perspective","volume":"19","author":"Alkhatib","year":"2024","journal-title":"PLoS One"},{"key":"R56-20260629","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(18)32196-2","article-title":"Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: An international, randomised, double-blind, phase 3 non-inferiority study","volume":"393","author":"Ye","year":"2019","journal-title":"Lancet"},{"key":"R57-20260629","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ueg2.12682","article-title":"Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment","volume":"13","author":"D'Amico","year":"2025","journal-title":"United European Gastroenterol J"},{"key":"R58-20260629","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","article-title":"Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase III study","volume":"38","author":"Papp","year":"2024","journal-title":"BioDrugs"},{"key":"R59-20260629","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/14712598.2023.2235263","article-title":"Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis","volume":"23","author":"Feldman","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"R60-20260629","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: The efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R61-20260629","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1136\/gutjnl-2019-319758","article-title":"Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: A prospective randomised trial","volume":"69","author":"Roblin","year":"2020","journal-title":"Gut"},{"key":"R62-20260629","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: Definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"R63-20260629","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/ajg.2014.146","article-title":"Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases","volume":"109","author":"Roblin","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R64-20260629","doi-asserted-by":"crossref","first-page":"897936","DOI":"10.3389\/fmed.2022.897936","article-title":"Management of Non-response and loss of response to anti-tumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"Marsal","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R65-20260629","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/cer-2017-0022","article-title":"Efficacy and safety of ustekinumab in the induction therapy of TNF-a-refractory Crohn's disease patients: A systematic review and meta-analysis","volume":"6","author":"Kawalec","year":"2017","journal-title":"J Comp Eff Res"},{"key":"R66-20260629","doi-asserted-by":"crossref","first-page":"e882","DOI":"10.1002\/hsr2.882","article-title":"Efficacy and safety of etrolizumab in treatment of moderate to severe ulcerative colitis: A systematic review and meta-analysis","volume":"7","author":"Motawea","year":"2024","journal-title":"Health Sci Rep"},{"key":"R67-20260629","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"R68-20260629","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/apt.15745","article-title":"Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment","volume":"52","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R69-20260629","first-page":"e28536","article-title":"The long-term clinical effectiveness of ustekinumab in antitumor necrosis factor-experienced Crohn's disease patients","volume":"14","author":"Altuwaijri","year":"2022","journal-title":"Cureus"},{"issue":"(Supplement_1)","key":"R70-20260629","doi-asserted-by":"crossref","first-page":"i1523","DOI":"10.1093\/ecco-jcc\/jjad212.0953","article-title":"P823 Real-world effectiveness of upadacitinib in Crohn's disease;A UK multicentre retrospective cohort study","volume":"18","author":"Elford","year":"2024","journal-title":"J Crohn's Colitis"},{"key":"R71-20260629","doi-asserted-by":"crossref","first-page":"105","DOI":"10.9734\/jammr\/2024\/v36i95561","article-title":"Comparative efficacy of anti-tumor necrosis factor (TNF) Therapy in inducing and maintaining remission from Crohn's disease: A systematic review and meta-analysis","volume":"36","author":"Mirza","year":"2024","journal-title":"J Adv Med Med Res"},{"key":"R72-20260629","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000517961","article-title":"Stopping anti-TNF in CD remitters: Cons","volume":"7","author":"Kobayashi","year":"2021","journal-title":"Inflamm Intest Dis"},{"key":"R73-20260629","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","article-title":"Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease","volume":"128","author":"Lichtenstein","year":"2005","journal-title":"Gastroenterology"},{"key":"R74-20260629","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"issue":"10","key":"R75-20260629","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.14309\/ajg.0000000000003406","article-title":"IL-23p19 Antagonists vs Ustekinumab for Treatment of Crohn's Disease: A Meta-Analysis of Randomized Controlled Trials","volume":"120","author":"Dziegielewski","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"R76-20260629","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"R77-20260629","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"R78-20260629","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R79-20260629","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"R80-20260629","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R81-20260629","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/1751-2980.12184","article-title":"A review of methotrexate-associated hepatotoxicity","volume":"15","author":"Bath","year":"2014","journal-title":"J Dig Dis"},{"key":"R82-20260629","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40261-023-01252-z","article-title":"Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: A post hoc analysis of a randomised clinical trial","volume":"43","author":"D'Haens","year":"2023","journal-title":"Clin Drug Investig"},{"key":"R83-20260629","doi-asserted-by":"crossref","first-page":"izaf038","DOI":"10.1093\/ibd\/izaf038","article-title":"Comparing outcomes with subcutaneous infliximab (CT-P13 SC) by baseline immunosuppressant use: A post hoc analysis of the LIBERTY-CD and LIBERTY-UC studies","volume":"31","author":"Schreiber","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"R84-20260629","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/MIB.0000000000001203","article-title":"Systematic review and meta-analysis: Adalimumab monotherapy versus combination therapy with immunomodulators for induction and maintenance of remission and response in patients with Crohn's disease","volume":"23","author":"Chalhoub","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R85-20260629","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/ecco-jcc\/jjw152","article-title":"Adalimumab monotherapy and a combination with azathioprine for Crohn's disease: A prospective, randomized trial","volume":"10","author":"Matsumoto","year":"2016","journal-title":"J Crohns Colitis"},{"key":"R86-20260629","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1097\/MIB.0000000000001126","article-title":"Therapeutic drug monitoring to guide infliximab dose adjustment is associated with better endoscopic outcomes than clinical decision making alone in active inflammatory bowel disease","volume":"23","author":"Kelly","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"R87-20260629","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: Predicting and optimising response to anti-TNF therapy in Crohn's disease \u2013 algorithm for practical management","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R88-20260629","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"R89-20260629","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ajg.2021.01.001","article-title":"Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort","volume":"22","author":"Azzam","year":"2021","journal-title":"Arab J Gastroenterol"},{"key":"R90-20260629","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.cgh.2021.10.002","article-title":"Effectiveness of reinduction and\/or dose escalation of Ustekinumab in Crohn's disease: A systematic review and meta-analysis","volume":"20","author":"Meserve","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R91-20260629","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000543831","article-title":"Efficacy of dose escalation of ustekinumab in inflammatory bowel disease: A systematic review and meta-analysis","volume":"34","author":"Rehman","year":"2025","journal-title":"Med Princ Pract"},{"key":"R92-20260629","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","article-title":"Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): An open-label, multicentre, randomised phase 3b trial","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R93-20260629","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1590\/S0004-28032014000400004","article-title":"Perianal complete remission with combined therapy (seton placement and anti-TNF agents) in Crohn's disease: A Brazilian multicenter observational study","volume":"51","author":"Kotze","year":"2014","journal-title":"Arq Gastroenterol"},{"key":"R94-20260629","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2468-1253(22)00088-7","article-title":"Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): A patient preference randomised trial","volume":"7","author":"Meima-van Praag","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R95-20260629","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1365-2036.2004.02247.x","article-title":"Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: A double-blind placebo-controlled study","volume":"20","author":"West","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"R96-20260629","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10350-004-6611-4","article-title":"Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: A single center experience","volume":"46","author":"Topstad","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"R97-20260629","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MEG.0000000000001634","article-title":"Predictors of long-term outcomes of radiologically defined perianal fistulizing Crohn's disease treated with antitumor necrosis factor-alpha agents based on Parks'classification","volume":"32","author":"Azzam","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R98-20260629","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1007\/s10620-019-05635-1","article-title":"Strategies to optimize anti-tumor necrosis factor therapy for perianal fistulizing Crohn's disease: A systematic review","volume":"64","author":"Tandon","year":"2019","journal-title":"Dig Dis Sci"},{"key":"R99-20260629","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/ibd.21940","article-title":"Long-term MRI-guided combined anti-TNF-\u03b1 and thiopurine therapy for Crohn's perianal fistulas","volume":"18","author":"Tozer","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"R100-20260629","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/00365521.2019.1600014","article-title":"Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients","volume":"54","author":"Strik","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"R101-20260629","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/apt.13970","article-title":"Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease","volume":"45","author":"Yarur","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"R102-20260629","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cgh.2024.08.032","article-title":"Efficacy and safety of Upadacitinib for perianal fistulizing Crohn's disease: A post hoc analysis of 3 phase 3 trials","volume":"23","author":"Colombel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R103-20260629","first-page":"244","article-title":"Safety and positioning of vedolizumab in patients with inflammatory bowel disease","volume":"14","author":"Feagan","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"R104-20260629","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cgh.2021.09.028","article-title":"Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn's disease: Enterprise study","volume":"20","author":"Schwartz","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R105-20260629","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5217\/ir.2021.00091","article-title":"Vedolizumab for perianal fistulizing Crohn's disease: Systematic review and meta-analysis","volume":"20","author":"Ayoub","year":"2022","journal-title":"Intest Res"},{"key":"R106-20260629","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.dld.2024.05.009","article-title":"Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU","volume":"56","author":"Casanova","year":"2024","journal-title":"Dig Liver Dis"},{"key":"R107-20260629","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: Results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R108-20260629","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s10620-023-08252-1","article-title":"Comparative efficacy of subcutaneous and intravenous infliximab and vedolizumab for maintenance treatment of TNF-naive adult patients with inflammatory bowel disease: A systematic literature review and network meta-analysis","volume":"69","author":"Peyrin-Biroulet","year":"2024","journal-title":"Dig Dis Sci"},{"key":"R109-20260629","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: The REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R110-20260629","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/apt.17822","article-title":"Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study","volume":"59","author":"Buisson","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"R111-20260629","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.dld.2019.05.027","article-title":"Anti-TNF\u03b1 agents are the best choice in preventing postoperative Crohn's disease: A meta-analysis","volume":"51","author":"Er\u0151s","year":"2019","journal-title":"Dig Liver Dis"},{"key":"R112-20260629","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1053\/j.gastro.2016.02.072","article-title":"Infliximab reduces endoscopic, but not clinical, recurrence of Crohn's disease after ileocolonic resection","volume":"150","author":"Regueiro","year":"2016","journal-title":"Gastroenterology"},{"key":"R113-20260629","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2468-1253(24)00317-0","article-title":"Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): A multicentre, double-blind, randomised, placebo-controlled trial","volume":"10","author":"D'Haens","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R114-20260629","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/apt.12644","article-title":"Systematic review with network meta-analysis: The efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R115-20260629","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"R116-20260629","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"R117-20260629","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"R118-20260629","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: Ulcerative colitis in adults","volume":"120","author":"Rubin","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"R119-20260629","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"R120-20260629","doi-asserted-by":"crossref","first-page":"e0212989","DOI":"10.1371\/journal.pone.0212989","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"key":"R121-20260629","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R122-20260629","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"R123-20260629","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: An updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R124-20260629","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3390\/biomedicines12051119","article-title":"Remission factors for Ustekinumab treatment of ulcerative colitis: A multicenter retrospective study of real-world data in Japan","volume":"12","author":"Omori","year":"2024","journal-title":"Biomedicines"},{"key":"R125-20260629","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/ibd\/izac275","article-title":"Efficacy, effectiveness, and safety of Ustekinumab for the treatment of ulcerative colitis: A systematic review","volume":"30","author":"Gisbert","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R126-20260629","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D'Haens","year":"2023","journal-title":"N Engl J Med"},{"key":"R127-20260629","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: Two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"R128-20260629","doi-asserted-by":"crossref","first-page":"i1146","DOI":"10.1093\/ecco-jcc\/jjad212.0723","article-title":"P593 Efficacy of Risankizumab in patients with moderately to severely active ulcerative colitis by prior advanced therapy failure and mechanism of action:Post hoc analysis of the INSPIRE and COMMAND phase 3 studies","volume":"18","author":"Panaccione","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R129-20260629","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): Phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"R130-20260629","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"R131-20260629","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"R132-20260629","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): A phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"R133-20260629","doi-asserted-by":"crossref","first-page":"1420455","DOI":"10.3389\/fphar.2024.1420455","article-title":"Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: A systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Qiu","year":"2024","journal-title":"Front Pharmacol"},{"key":"R134-20260629","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"R135-20260629","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): Two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"R136-20260629","first-page":"e39372","article-title":"Safety and efficacy of S1P receptor modulators for the induction and maintenance phases in inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials","volume":"103","author":"Akram","year":"2024","journal-title":"N Engl J Med"},{"key":"R137-20260629","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"R138-20260629","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1007\/s10620-023-07825-4","article-title":"Vedolizumab and adalimumab in biologic-na\u00efve ulcerative colitis: Comparison of patient-level clinical trial data and VARSITY for week 6 clinical remission","volume":"68","author":"Narula","year":"2023","journal-title":"Dig Dis Sci"},{"key":"R139-20260629","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"R140-20260629","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10238-025-01558-6","article-title":"Biosimilars versus biological therapy in inflammatory bowel disease: Challenges and targeting strategies using drug delivery systems","volume":"25","author":"Aljabri","year":"2025","journal-title":"Clin Exp Med"},{"key":"R141-20260629","first-page":"603","article-title":"Systematic review with meta-analysis: Infliximab and immunosuppressant therapy vs","volume":"41","author":"Christophorou","year":"2015","journal-title":"infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther"},{"key":"R142-20260629","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"R143-20260629","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1093\/ecco-jcc\/jjy109","article-title":"Clinical outcomes with therapeutic drug monitoring in inflammatory bowel disease: A systematic review with meta-analysis","volume":"12","author":"Ricciuto","year":"2018","journal-title":"J Crohns Colitis"},{"key":"R144-20260629","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4103\/sjg.sjg_3_22","article-title":"Therapeutic drug monitoring for biological medications in inflammatory bowel disease","volume":"28","author":"Cogan","year":"2022","journal-title":"Saudi J Gastroenterol"},{"key":"R145-20260629","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.cgh.2021.03.028","article-title":"Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: A multicenter cohort study","volume":"20","author":"Dalal","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R146-20260629","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s10620-020-06486-x","article-title":"Vedolizumab dose escalation improves therapeutic response in a subset of patients with ulcerative colitis","volume":"66","author":"Perry","year":"2021","journal-title":"Dig Dis Sci"},{"key":"R147-20260629","doi-asserted-by":"crossref","first-page":"S442","DOI":"10.1093\/ecco-jcc\/jjz203.639","article-title":"P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data","volume":"14","author":"Sandborn","year":"2020","journal-title":"J Crohns Colitis"},{"key":"R148-20260629","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/ecco-jcc\/jjae079","article-title":"Impact of prior biologic or janus kinase inhibitor therapy on efficacy and safety of etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"18","author":"Vermeire","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R149-20260629","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ecco-jcc\/jjad212.0014","article-title":"OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis","volume":"18","author":"Hart","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R150-20260629","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12876-022-02225-w","article-title":"Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment","volume":"22","author":"Hyun","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"R151-20260629","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/sjg.sjg_249_24","article-title":"The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the inflammatory bowel disease of the middle east (IBD-ME) registry group","volume":"31","author":"Azzam","year":"2025","journal-title":"Saudi J Gastroenterol"},{"key":"R152-20260629","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/ecco-jcc\/jjaa226","article-title":"Ciclosporin or infliximab as rescue therapy in acute glucorticosteroid-refractory ulcerative colitis: Systematic review and network meta-analysis","volume":"15","author":"Barberio","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R153-20260629","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20440","article-title":"Comparison of iNfliximab and ciclosporin in STeroid resistant ulcerative colitis: Pragmatic randomised Trial and economic evaluation (CONSTRUCT)","volume":"20","author":"Williams","year":"2016","journal-title":"Health Technology Assessment"},{"key":"R154-20260629","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study","volume":"128","author":"J\u00e4rnerot","year":"2005","journal-title":"Gastroenterology"},{"key":"R155-20260629","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1572-0241.2007.01718.x","article-title":"Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease","volume":"103","author":"Sternthal","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R156-20260629","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): A randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"R157-20260629","doi-asserted-by":"crossref","first-page":"i155","DOI":"10.1093\/ecco-jcc\/jjad212.0086","article-title":"DOP46 Tofacitinib for hospitalized acute severe Ulcerative Colitis \u2013 the TRIUMPH study","volume":"18","author":"Narula","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R158-20260629","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S2468-1253(24)00200-0","article-title":"Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): An open-label, multicentre, randomised controlled trial","volume":"9","author":"Choy","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R159-20260629","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cgh.2014.07.041","article-title":"An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis","volume":"13","author":"Gibson","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R160-20260629","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"R161-20260629","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ibd\/izad166","article-title":"Safety, effectiveness, and treatment persistence of subcutaneous vedolizumab in IBD: A multicenter study from the United Kingdom","volume":"30","author":"Lim","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R162-20260629","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ibd\/izad094","article-title":"One-year clinical outcomes of subcutaneous infliximab maintenance therapy compared with intravenous infliximab maintenance therapy in patients with inflammatory bowel disease: A prospective cohort study","volume":"30","author":"Hong","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R163-20260629","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): A 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"R164-20260629","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.3748\/wjg.v30.i46.4904","article-title":"Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease","volume":"30","author":"Liu Chen Kiow","year":"2024","journal-title":"World J Gastroenterol"},{"key":"R165-20260629","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ibd\/izab099","article-title":"Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: A prospective multicenter cohort study","volume":"28","author":"Hanzel","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"R166-20260629","doi-asserted-by":"crossref","first-page":"17562848241301887","DOI":"10.1177\/17562848241301887","article-title":"Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: Results of a prospective long-term cohort study","volume":"17","author":"Fischer","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"R167-20260629","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2208450","article-title":"Vedolizumab for the treatment of chronic pouchitis","volume":"388","author":"Travis","year":"2023","journal-title":"N Engl J Med"},{"key":"R168-20260629","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2023.10.015","article-title":"AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders","volume":"166","author":"Barnes","year":"2024","journal-title":"Gastroenterology"},{"key":"R169-20260629","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: A systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R170-20260629","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/03007995.2023.2194782","article-title":"The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: Results from medical charts in the United Kingdom","volume":"39","author":"Lindsay","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"R171-20260629","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00384-023-04397-7","article-title":"Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany","volume":"38","author":"Bokemeyer","year":"2023","journal-title":"Int J Colorectal Dis"},{"key":"R172-20260629","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/ecco-jcc\/jjab112","article-title":"ECCO topical review: Refractory inflammatory bowel disease","volume":"15","author":"Raine","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R173-20260629","first-page":"251","article-title":"Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease","volume":"19","author":"Solitano","year":"2023","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"R174-20260629","doi-asserted-by":"crossref","first-page":"otac002","DOI":"10.1093\/crocol\/otac002","article-title":"Systematic review with meta-analysis: Safety and effectiveness of combining biologics and small molecules in inflammatory bowel disease","volume":"4","author":"Alayo","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"R175-20260629","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): A randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R176-20260629","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.cgh.2023.09.010","article-title":"Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn's disease (EXPLORER)","volume":"22","author":"Colombel","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_277_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:52:27Z","timestamp":1786647147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_277_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":176,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_277_25","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"2025-07-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}